Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNGT89)

Drug Name
Lirilumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [2]
Myelodysplastic syndrome 2A37 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Cross-matching ID
TTD Drug ID
DMNGT89

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RAS-like protein KIR (GEM) TTAZF9M GEM_HUMAN Modulator [4]

References

1 ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40.